"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 1 | 3 |
| 2005 | 0 | 5 | 5 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 2 | 4 | 6 |
| 2012 | 0 | 4 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 6 | 6 |
| 2015 | 2 | 4 | 6 |
| 2016 | 3 | 2 | 5 |
| 2017 | 1 | 9 | 10 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 3 | 4 |
| 2020 | 1 | 6 | 7 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
?c cytokine-aided crosstalk between dendritic cells and natural killer cells together with doxorubicin induces a healer response in experimental lymphoma by downregulating FOXP3 and programmed cell death protein 1. Cytotherapy. 2022 Dec; 24(12):1232-1244.
-
Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Int J Cardiol. 2021 Sep 15; 339:146-149.
-
Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis). BMC Cancer. 2021 Apr 06; 21(1):358.
-
Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population. Leuk Lymphoma. 2021 08; 62(8):1869-1876.
-
An Electrochemical Strategy for the Simultaneous Detection of Doxorubicin and Simvastatin for Their Potential Use in the Treatment of Cancer. Biosensors (Basel). 2021 Jan 03; 11(1).
-
Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):162-169.
-
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. BJU Int. 2021 05; 127(5):528-537.
-
Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa. Expert Rev Gastroenterol Hepatol. 2020 Oct; 14(10):1007-1011.
-
MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era. Leuk Res. 2020 10; 97:106426.
-
Perspectives on chemotherapy for the management of double-hit lymphoma. Expert Opin Pharmacother. 2020 Apr; 21(6):653-661.